Eli Lilly's Weight-Loss Drug Boom Fuels Wall Street Optimism, Despite Recent Pullback
While Eli Lilly's stock has cooled in 2026 after a historic rally, Wall Street analysts remain overwhelmingly bullish, betting the pharmaceutical giant's blockbuster obesity treatments will drive long-term growth.